Compare SEQUENT SCIENTIFIC with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SEQUENT SCIENTIFIC vs ADVANCED ENZYME TECHNOLOGIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SEQUENT SCIENTIFIC ADVANCED ENZYME TECHNOLOGIES SEQUENT SCIENTIFIC/
ADVANCED ENZYME TECHNOLOGIES
 
P/E (TTM) x 54.7 25.3 216.2% View Chart
P/BV x 6.1 3.9 156.3% View Chart
Dividend Yield % 0.3 0.2 159.3%  

Financials

 SEQUENT SCIENTIFIC   ADVANCED ENZYME TECHNOLOGIES
EQUITY SHARE DATA
    SEQUENT SCIENTIFIC
Mar-21
ADVANCED ENZYME TECHNOLOGIES
Mar-21
SEQUENT SCIENTIFIC/
ADVANCED ENZYME TECHNOLOGIES
5-Yr Chart
Click to enlarge
High Rs265417 63.6%   
Low Rs70129 54.1%   
Sales per share (Unadj.) Rs54.844.9 122.1%  
Earnings per share (Unadj.) Rs4.213.6 31.0%  
Cash flow per share (Unadj.) Rs6.216.1 38.8%  
Dividends per share (Unadj.) Rs0.500.60 83.3%  
Avg Dividend yield %0.30.2 135.8%  
Book value per share (Unadj.) Rs29.086.6 33.5%  
Shares outstanding (eoy) m248.37111.73 222.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x3.16.1 50.3%   
Avg P/E ratio x39.820.1 197.8%  
P/CF ratio (eoy) x26.817.0 158.2%  
Price / Book Value ratio x5.83.1 183.4%  
Dividend payout %11.94.4 268.6%   
Avg Mkt Cap Rs m41,59030,491 136.4%   
No. of employees `000NANA-   
Total wages/salary Rs m1,872871 214.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m13,6165,018 271.3%  
Other income Rs m8488 94.5%   
Total revenues Rs m13,7005,107 268.3%   
Gross profit Rs m2,0322,325 87.4%  
Depreciation Rs m506284 178.1%   
Interest Rs m24426 954.3%   
Profit before tax Rs m1,3662,104 64.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m322589 54.6%   
Profit after tax Rs m1,0451,515 69.0%  
Gross profit margin %14.946.3 32.2%  
Effective tax rate %23.628.0 84.1%   
Net profit margin %7.730.2 25.4%  
BALANCE SHEET DATA
Current assets Rs m7,6675,161 148.6%   
Current liabilities Rs m5,140676 760.8%   
Net working cap to sales %18.689.4 20.8%  
Current ratio x1.57.6 19.5%  
Inventory Days Days31102 30.4%  
Debtors Days Days9363 147.9%  
Net fixed assets Rs m6,7636,297 107.4%   
Share capital Rs m497223 222.3%   
"Free" reserves Rs m6,7029,457 70.9%   
Net worth Rs m7,1999,680 74.4%   
Long term debt Rs m93799 949.3%   
Total assets Rs m14,43011,458 125.9%  
Interest coverage x6.683.3 7.9%   
Debt to equity ratio x0.10 1,276.5%  
Sales to assets ratio x0.90.4 215.4%   
Return on assets %8.913.4 66.4%  
Return on equity %14.515.6 92.7%  
Return on capital %19.821.8 90.9%  
Exports to sales %012.9 0.0%   
Imports to sales %05.9 0.0%   
Exports (fob) Rs mNA648 0.0%   
Imports (cif) Rs mNA298 0.0%   
Fx inflow Rs m686648 105.9%   
Fx outflow Rs m281298 94.5%   
Net fx Rs m405351 115.5%   
CASH FLOW
From Operations Rs m1,1481,629 70.4%  
From Investments Rs m96-260 -37.1%  
From Financial Activity Rs m-1,388-263 527.4%  
Net Cashflow Rs m-1441,093 -13.1%  

Share Holding

Indian Promoters % 0.0 12.2 -  
Foreign collaborators % 53.0 40.6 130.7%  
Indian inst/Mut Fund % 8.6 25.4 33.7%  
FIIs % 6.4 16.4 39.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 47.0 47.3 99.3%  
Shareholders   167,812 84,346 199.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SEQUENT SCIENTIFIC With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Nazara Tech's Acquisition in Ad Tech Company, boAt-Dixon Technologies form JV, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a weak note yesterday. Benchmark indices witnessed heavy selling in the fag-end of the session as weak global cues.

Related Views on News

ADVANCED ENZYME TECHNOLOGIES 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of ADVANCED ENZYME TECHNOLOGIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of ADVANCED ENZYME TECHNOLOGIES. Also includes updates on the valuation of ADVANCED ENZYME TECHNOLOGIES.

SEQUENT SCIENTIFIC 2020-21 Annual Report Analysis (Annual Result Update)

Oct 25, 2021 | Updated on Oct 25, 2021

Here's an analysis of the annual report of SEQUENT SCIENTIFIC for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SEQUENT SCIENTIFIC. Also includes updates on the valuation of SEQUENT SCIENTIFIC.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

India's Best Semiconductor Stocks(Views On News)

Jan 7, 2022

Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Looking for Consistent Compounding Stocks? Here's a Watchlist for You(Views On News)

Jan 6, 2022

These companies have generated mind boggling returns for investors over the years.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SEQUENT SCIENTIFIC SHARE PRICE


Jan 18, 2022 (Close)

TRACK SEQUENT SCIENTIFIC

  • Track your investment in SEQUENT SCIENTIFIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SEQUENT SCIENTIFIC

SEQUENT SCIENTIFIC - ORCHID PHARMA COMPARISON

COMPARE SEQUENT SCIENTIFIC WITH

MARKET STATS